Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Uterine Cancer

New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

Ulas D. Bayraktar, MD

Head and Neck Cancer

New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

Ulas D. Bayraktar, MD

Waldenstrom macroglobulinemia

New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom

Ulas D. Bayraktar, MD

Multiple Myeloma

New Drug: Teclistamab in R/R Multiple Myeloma

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Drug: Futibatinib for Cholangicarcinoma

Ulas D. Bayraktar, MD

Renal Cell Carcinoma

New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC

Ulas D. Bayraktar, MD

Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Ulas D. Bayraktar, MD

Colorectal Cancer

New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer

Ulas D. Bayraktar, MD

Uterine Cancer

New Drug: Dostarlimab for Endometrial Cancer

Ulas D. Bayraktar, MD

New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

Phase II, multicenter, single-arm study (STATICE) Pretreated advanced or recurrent HER2-expressing UCS Trastuzumab Deruxtecan: HER 2:1+ (low group, n=10) vs. HER 22+ (high grou

Head and Neck Cancer

New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

• Open-label,single-arm, phase 2 study Pretreated metastatic or recurrent ACC Axitinib + Avelumab q28 (n=28)

Waldenstrom macroglobulinemia

New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom

Prospectively Randomized , phase 3 trial Treatment naïve Waldenström's macroglobulinemia (WM) Bortezomib, dexamethasone, rituximab, and cyclophosphamide (B-DRC ) vs. DRC

Multiple Myeloma

New Drug: Teclistamab in R/R Multiple Myeloma

Single-arm, multi-cohort, open-label, multicenter, phase 1/2 study Relapsed or refractory myeloma after at least three therapy lines (n=165) Teclistamab sc weekly

Biliary Tract Cancer

New Drug: Futibatinib for Cholangicarcinoma

A single-arm, multicenter, phase 2 study Advanced/metastatic unresectable iCCA harboring FGFR2 gene fusions Disease progression after ≥1 line of systemic therapy Futibatinib 20 m

Renal Cell Carcinoma

New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC

Single-arm, open-label, multicenter, phase II trial Previously untreated stage IV non-clear cell renal cell carcinoma Pembrolizumab + Lenvatinib (n=158

Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Randomised, open-label, phase 3 study (KEYNOTE-177) Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer Pembrolizumab 200 mg every 3

Colorectal Cancer

New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer

Single-arm, multicenter, Phase-2 trial Previosly untreated, BRAF V600E mutant Colorectal cancer Encorafenib + Binimetinib + Cetuximab q28 (n=95)

New Drug: Dostarlimab for Endometrial Cancer

Multicenter, multicohort, open-abel trial (GARNET) dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen Dostarlimab-gxly q21 (

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag